Skip to Content

Bausch & Lomb Corp

BLCO: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$34.00HmwgvwPyqxfhcp

Restarting Coverage of Bausch & Lomb With $25 Fair Value Estimate

Business Strategy and Outlook

As a new public company, Bausch & Lomb will be primarily focused on ramping up research and development to become more competitive in its key markets of contact lens and solution, eyecare surgery, and ophthalmic pharmaceuticals.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of BLCO so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center